Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
Selected early stage assets with the potential to deliver
high-impact medicines for patients
INNOVATION
Compound Therapeutic area
МоА
Indication(s)
Current phase
Next milestone
XXB750
Cardiovascular
NPR1 agonist
Hypertension
Ph2b
Ph2b readout 2024
Heart failure
YTB323
Hematology O CD19 RAPID CART
1L HR LBCL
Ph2
Data readout(s) 2024/2025
Immunology
Multiple indications
being explored
AAA603
Solid Tumors
Radioligand therapy
targeting GRPR
Breast cancer
Ph1
Ph1 readout - H2 2023
Glioblastoma
PPY988
Ophthalmology
Gene therapy - Complement
factor I modulation
Geographic atrophy
Ph2b
Topline data - 2024
DLX313
Neuroscience
a-Synuclein inhibitor
Parkinson's
Ph2a
Topline data - 2024
NPR1 natriuretic peptide receptor 1.
CART - chimeric androgen receptor T. LBCL - large B-cell lymphoma. GRPR gastrin releasing peptide receptor.
20 Investor Relations | Q4 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation